About Us
Our Impact
Research & Services
Resources
Donate

About Us
Our Impact
Research & Services
Resources
Donate

Pipeline

Scientist in laboratory looking through a microscope

RPGRIP1
USH1C
USH2A
CLRN1

Questions? We’re here to help!

Services

Services Overview
Brydge Solutions

Science

Research and Development
Our Mission

Resources

Resources
Webinars and Presentations
Clinical Trials

Latest News

Odylia to Host an Update on the RPGRIP1 Gene Therapy Program and Plans for 2022, Feb 3rd
Odylia Therapeutics Granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for OT-004, an Investigational Gene Therapy for RPGRIP1- associated Retinal Dystrophies
Odylia announces new partnership with CLOVES Syndrome Community

© 2020 Odylia Therapeutics | Web Site by Hester Designs LLC.